Corindus Vascular Robotics Inc
Corindus Vascular Robotics — Investor Presentation (January 2018)
13 slides from Corindus Vascular Robotics's investor presentation, Jan 8, 2018
Slide 1: Precision Vascular Robotics
1 Precision Vascular Robotics Corindus Vascular Robotics (CVRS) January 2018
Slide 2: Forward Looking Statements
Forward Looking Statements This presentation contains “forward - looking statements” (as such term is defined in Section 27 A of the Securities Act of 1933 , as amended, and Section 21 E of the Securities Exchange Act of 1934 , as amended), and information relating to the company, that are based on
Slide 3: Corindus Today: A leader in vascular robotics
Corindus Today A leader in vascular robotics LARGE Market Opportunity with Long GROWTH Runway $4.5B 1 market opportunity in 2018 driven by over 2.5 million coronary and 3 million non - coronary procedures performed per year DIFFERENTIATED Technology ONLY FDA cleared robotic platform for percutaneous
Slide 4: Interventional Market Opportunity
1 Market opportunity assessment based on market research reports and Corindus estimate 2 Peripheral Vascular includes lower limb, carotid, renal, iliac and AAA (abdominal aortic aneurysm) procedures 3 Millennium Research Group Interventional Market Opportunity Large & growing worldwide market • $4.5
Slide 5: Company Milestones
Company Milestones 5 Next Generation CorPath GRX cleared by FDA with Guide Catheter Control and Enhanced User Interface CorPath GRX seeing high utilization in cath labs & 2x increase in adoption with existing customers Adoption Global Signed Distribution Agreement with 2 nd largest company in Japan
Slide 6: Robotics in the Cath Lab
Robotics in the Cath Lab 6 Second Generation Robotic - assisted PCI System BEDSIDE UNIT • Optimized bedside unit for radial access • Simple setup & in - procedure workflow • Devices fixed during intervention • Imaging and device agnostic INTERVENTIONAL COCKPIT • Precise robotic control of x Guide ca
Slide 7: Traditional PCI vs Robotic PCI
Struggle to see angiography Close proximity ergonomic visualization Trial & error, wire spinning Precise ‘Point & Shoot’ predictability ‘Eyeball’ estimate Robotic - assisted sub - mm Measurement Manual adjustment 1mm precise positioning Devices loose during inflation Fixated devices during deploymen
Slide 8: Why Vascular Robotics
Why Vascular Robotics 8 Benefits for patients, physicians, & hospitals DIFFERENTIATION • Position hospital on the cutting edge by deploying robotics as part of a hi - tech cardiology model • Clinical leadership • Attract & retain physicians PATIENT BENEFIT • Robotic precision reduces stent utilizati
Slide 9: Evolution of Interventional Treatment
Evolution of Interventional Treatment 9 Hi - tech cardiology model with robotics Occupational Hazards High risk working environment Physician burnout Traditional PCI Stagnant Market Competition for market share Radial adoption slow Precise Treatment Precise robotic movement Enhanced visualization Mu
Slide 10: Vascular Robotic Clinical Roadmap
Vascular Robotic Clinical Roadmap Demonstrating excellence in multiple lesion types and anatomies Product Evolution Robotic system capability Exploratory Feasibility Expand Use NEURO PERIPHERAL PCI 10 CorPath 200 and CorPath GRX Systems are indicated for PCI. Only the CorPath 200 System is indicated
Slide 11: Clinical Leadership
Clinical Leadership 11 J. Aaron Grantham, MD Saint Luke's Hospital of Kansas City Marty Leon, MD NewYork - Presbyterian Hospital Louis Cannon, MD BioStar Ventures Campbell Rogers, MD HeartFlow Steven Almany, MD Beaumont Hospital David Kandzari, MD Piedmont Heart Bill Lombardi, MD University of Washi
Slide 12: Catalysts & Strategic Objectives
12 Catalysts & Strategic Objectives Software Enhancements 1st Automated Movement Expanding Indications Peripheral Japan Commercial Launch Remote Capabilities Telestenting China Planned Expansion 2018 2019 - 2020 2021 - 2023 FOUNDATION : THREE PILLARS OF GROWTH Technology Development Market Expansion
Slide 13: About Corindus Vascular Robotics
Corindus Vascular Robotics, Inc. is a global technology leader in robotic - assisted vascular interventions. The company's CorPath ® System is the first FDA - cleared medical device to bring robotic - assisted precision to percutaneous coronary interventions. With the CorPath System, Corindus Vascul
Corindus Vascular Robotics — Investor Presentation (January 2018) on 6ix